Name | 5-[4-phenyl-5-(trifluoromethyl)thiophen-2-yl]-3-[3-(trifluoromethyl)phenyl]-1,2,4-oxadiazole |
---|---|
Synonyms |
1,2,4-Oxadiazole, 5-[4-phenyl-5-(trifluoromethyl)-2-thienyl]-3-[3-(trifluoromethyl)phenyl]-
5-[4-Phenyl-5-(trifluoromethyl)-2-thienyl]-3-[3-(trifluoromethyl)phenyl]-1,2,4-oxadiazole 5-[4-phenyl-5-(trifluoromethyl)thiophen-2-yl]-3-[3-(trifluoromethyl)phenyl]-1,2,4-oxadiazole 5-[4-Phenyl-5-(trifluoromethyl)-2-thienyl]-3-[3-(trifluoromethyl)phenyl]- 1,2,4-oxadiazole 5-[4-phenyl-5-(trifluoromethyl)thien-2-yl]-3-[3-(trifluoromethyl)phenyl]-1,2,4-oxadiazole |
Description | SEW2871 is a highly selective, orally active S1P1 agonist with an EC50 of 13.8 nM. SEW2871 activates ERK, Akt, and Rac signaling pathways and induces S1P1 internalization and recycling. SEW2871 reduces lymphocyte numbers in blood and has therapeutic implications in contexts of diabetes, Alzheimer’s disease, liver fibrosis, and inflammatory responses[1][2]. |
---|---|
Target |
EC50: 13.8 nM (S1P1)[2] |
References |
Density | 1.4±0.1 g/cm3 |
---|---|
Boiling Point | 490.3±55.0 °C at 760 mmHg |
Melting Point | 94.5-95.3ºC |
Molecular Formula | C20H10F6N2OS |
Molecular Weight | 440.362 |
Flash Point | 250.3±31.5 °C |
Exact Mass | 440.041809 |
PSA | 67.16000 |
LogP | 8.42 |
Vapour Pressure | 0.0±1.2 mmHg at 25°C |
Index of Refraction | 1.535 |